Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACLX
Upturn stock ratingUpturn stock rating

Arcellx Inc (ACLX)

Upturn stock ratingUpturn stock rating
$65.85
Last Close (24-hour delay)
Profit since last BUY-3.3%
upturn advisory
Consider higher Upturn Star rating
BUY since 16 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ACLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

18 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $111.13

1 Year Target Price $111.13

Analysts Price Target For last 52 week
$111.13Target price
Low$47.86
Current$65.85
high$107.37

Analysis of Past Performance

Type Stock
Historic Profit 29.66%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.60B USD
Price to earnings Ratio -
1Y Target Price 111.13
Price to earnings Ratio -
1Y Target Price 111.13
Volume (30-day avg) 18
Beta 0.28
52 Weeks Range 47.86 - 107.37
Updated Date 06/29/2025
52 Weeks Range 47.86 - 107.37
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.99

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -211.46%
Operating Margin (TTM) -847.56%

Management Effectiveness

Return on Assets (TTM) -16.69%
Return on Equity (TTM) -35.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3111150041
Price to Sales(TTM) 46.89
Enterprise Value 3111150041
Price to Sales(TTM) 46.89
Enterprise Value to Revenue 40.51
Enterprise Value to EBITDA -6.52
Shares Outstanding 55106700
Shares Floating 32731177
Shares Outstanding 55106700
Shares Floating 32731177
Percent Insiders 14.5
Percent Institutions 102.08

Analyst Ratings

Rating 4
Target Price 111.13
Buy 6
Strong Buy 12
Buy 6
Strong Buy 12
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Arcellx Inc

stock logo

Company Overview

overview logo History and Background

Arcellx, Inc. is a clinical-stage biotechnology company founded in 2015. It focuses on developing and commercializing adaptive cellular therapies for patients with cancer and other incurable diseases. The company has evolved from initial research stages to clinical trials, aiming to bring novel therapies to market.

business area logo Core Business Areas

  • Adaptive Cellular Therapy: Arcellx's primary focus is on developing and advancing its D- Domains technology to manufacture cellular therapies, especially for cancer treatment.

leadership logo Leadership and Structure

Arcellx is led by a management team with expertise in cell therapy development and commercialization. The company has a board of directors overseeing strategic direction. Specific names are easily accessible via their investor relations page.

Top Products and Market Share

overview logo Key Offerings

  • CART-ddBCMA (Anitocabtagene Autoleucel): A CAR-T cell therapy targeting BCMA (B-cell maturation antigen) for the treatment of relapsed or refractory multiple myeloma. This is the lead product candidate. Market share is currently N/A as it's in clinical trials, not yet commercialized. Competitors include approved BCMA-targeting therapies such as Abecma (bb2121, idecabtagene vicleucel) and Carvykti (cilta-cel).

Market Dynamics

industry overview logo Industry Overview

The cellular therapy industry is rapidly growing, driven by advancements in immunotherapy and the increasing prevalence of cancer. It's a competitive space with large pharmaceutical companies and smaller biotechs all vying for market share. High costs and complex manufacturing processes are key challenges.

Positioning

Arcellx aims to differentiate itself through its D-Domains technology platform, potentially offering advantages in efficacy, safety, and manufacturing scalability compared to existing CAR-T therapies. They are seeking to improve upon existing treatments and compete for market share

Total Addressable Market (TAM)

The TAM for multiple myeloma therapies is estimated to be in the billions of dollars annually. Arcellx is positioning itself to capture a significant share of this market with CART-ddBCMA, if approved. Specific TAM values are subject to market forecasts and vary.

Upturn SWOT Analysis

Strengths

  • Novel D-Domains technology platform
  • Promising early clinical data for CART-ddBCMA
  • Experienced management team
  • Strong intellectual property portfolio

Weaknesses

  • Reliance on single lead product candidate
  • Limited commercialization experience
  • High cash burn rate
  • Clinical trial risks and regulatory uncertainties

Opportunities

  • Potential for regulatory approval of CART-ddBCMA
  • Expansion of D-Domains platform to other cancer targets
  • Strategic partnerships with larger pharmaceutical companies
  • Positive clinical trial data updates

Threats

  • Competition from established CAR-T therapies
  • Adverse clinical trial results
  • Regulatory hurdles
  • Manufacturing challenges
  • Economic downturn and impact on investor sentiment

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • JNJ

Competitive Landscape

Arcellx's advantage lies in its novel D-Domains technology. Disadvantages include being a smaller company competing against larger, established players with approved products.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by advancement of the D-Domains technology platform and progression of CART-ddBCMA through clinical trials.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approval, and commercial launch of CART-ddBCMA. Analyst estimates project significant revenue growth if approved.

Recent Initiatives: Recent initiatives include ongoing clinical trials for CART-ddBCMA, expansion of the D-Domains platform to other indications, and potential partnerships.

Summary

Arcellx is a clinical-stage biotechnology company with promising technology in the CAR-T therapy space. Its success hinges on positive clinical trial results for CART-ddBCMA and subsequent regulatory approval. The company faces competition from established players, requires careful financial management, and carries inherent risks associated with drug development. However, success could result in high returns.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Arcellx Inc. Investor Relations
  • Company SEC Filings
  • Analyst Reports
  • Industry News and Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a financial professional. Market share data is estimated and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Arcellx Inc

Exchange NASDAQ
Headquaters Redwood City, CA, United States
IPO Launch date 2022-02-04
Chairman of the Board, CEO & President Mr. Rami Elghandour
Sector Healthcare
Industry Biotechnology
Full time employees 163
Full time employees 163

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.